Full text

Turn on search term navigation

© 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

ABSTRACT

Today, synthetic drugs with side effects on health are used as agents for treating diseases. Moreover, these agents are utilized in the treatment of one specific disease. Consequently, it is essential to develop natural systems that do not harm health and instead foster healing for a range of diseases upon consumption. Therefore, the study focused on examining the behavior of nanocarriers containing the combination of Quercus infectoria gall‐derived phenolic powder (GP) and pomegranate seed‐derived peptide (BP) on type 2 diabetes and hypertension in the in vitro gastrointestinal tract. Firstly, the plausible conditions (enzyme type: Alcalase and enzyme‐to‐protein ratio: 1/20, w/w) for BP production were performed. Nanoliposomal systems having four different natures were called B‐NL (nanoliposome prepared without phyto‐active), GP‐NL (phenolic‐loaded nanoliposome), BP‐NL (peptide‐loaded nanoliposome), and GPBP‐NL (both phenolic and peptide‐loaded nanoliposome). The conversion of protein to peptide resulted in the disappearance of characteristic protein bands in SDS‐PAGE. FTIR spectra indicated that physical interactions predominated within nanocarriers. SEM images showed the dominance of spherical structures for all samples. Particle size (228.90‐364.30 nm), polydispersity index (PDI: 0.10‐0.48), zeta potential (14.50‐17.00 mV), and encapsulation efficiency (EE: 86.33%–90.30%) of nanoliposomes were elaborated. Bioaccessibility of GP (40.05%) and BP (38.09%) was lower than those of their nano‐encased forms (85.92%–87.03%). Also, GP‐NL, BP‐NL, and GPBP‐NL displayed superior inhibition activity toward key enzymes associated with type 2 diabetes and hypertension in the micellar phase compared to their uncoated forms. Ultimately, innovative bifunctional nanocarriers with high potential for treating diabetes and hypertension were developed.

Details

Title
Dual‐Loaded Nanocarriers With High Stability in Gastrointestinal Tract for Type 2 Diabetes and Hypertension Prevention
Author
Yücetepe, Melike 1 ; Karakuş, Mehmet Şükrü 2 ; Akalan, Merve 1 ; Bayrak Akay, Kamile 1 ; Sağlam, Hidayet 3 ; Karaaslan, Asliye 4 ; Başyiğit, Bülent 1   VIAFID ORCID Logo  ; Karaaslan, Mehmet 1   VIAFID ORCID Logo 

 Food Engineering Department, Engineering Faculty, Harran University, Şanlıurfa, Türkiye 
 Harran University, Application and Research Center for Science and Technology, Şanlıurfa, Türkiye 
 Molecular Biology and Genetics Department, Arts and Sciences Faculty, Kilis 7 Aralık University, Kilis, Türkiye 
 Harran University, Vocational School, Food Processing Programme, Şanlıurfa, Türkiye 
Section
ORIGINAL ARTICLE
Publication year
2025
Publication date
Jun 1, 2025
Publisher
John Wiley & Sons, Inc.
e-ISSN
20487177
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3224228871
Copyright
© 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.